The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2016 | Improved overall survival in lung cancer patients using Moovcare compared to standard modalities

Name: Improved overall survival in lung cancer patients using Moovcare compared to standard modalities
Uploaded: 2016-06-03T00:00:00.000Z
Duration: 2 min 58 s
Description: Press brief by Fabrice Denis, MD, PhD of the Jean Bernard Center, Le Mans, France, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Fabrice Denis • 3 Jun 2016

ASCO 2016

Lung Cancer

Press brief by Fabrice Denis, MD, PhD of the Jean Bernard Center, Le Mans, France, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.